Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Questcor Pharmaceuticals
August 11, 2015
Mallinckrodt buys cancer cell therapy for $1.3bn
July 23, 2014
Sovaldi not the first to break the bank
April 10, 2014
Q1 M&A data underline strong sentiment in life science sector
April 08, 2014
Mallinckrodt dashes hopes of a return to valuation fundamentals
April 07, 2014
Big pharma benefits from biotech carnage in Q1
February 13, 2014
Retrophin moves a step closer to becoming the new Questcor
June 12, 2013
Questcor gives the bulls another short-term reason to cheer
January 07, 2013
All change as big pharma rounds off a stellar 2012
January 04, 2013
BioVectra deal shows Questcor’s faith in Acthar
November 30, 2012
Big beasts exert influence as biotech comes back from the dead
October 09, 2012
Big pharma and biotech shines in first nine months of 2012
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
September 22, 2022
ESMO 2022 eBook
September 01, 2022
PD(L)anner – September 2022
Editor's Picks
July 27, 2022
Aids 2022 preview – Gilead shoots for an HIV cure
July 21, 2022
Private equity gets serious about drug development
July 18, 2022
Unpacking Royalty Pharma
July 19, 2022
No plain sailing for Novartis’s PD-1 plan
July 26, 2022
Move over Aduhelm, it’s tofersen’s turn
